AstraZeneca’s Sone-Ve: Longer Survival, but a Primary Endpoint Missed

Company: AstraZeneca (NASDAQ: AZN)
Program: sonesitatug vedotin (Sone-Ve), an investigational CLDN18.2-targeted antibody–drug conjugate
Evidence cutoff: October 26, 2026

A gastric cancer drug doubled median overall survival in one patient population, from five months to ten. Yet another primary endpoint in the same trial did not reach statistical significance.

How should investors assess that result?

AstraZeneca released detailed Phase 3 CLARITY-Gastric01 findings on October 25, 2026.[1] Understanding the evidence starts with placing each result in its intended population and endpoint hierarchy.

Three results that need to stay distinct

The company reported the following comparisons with investigator’s choice of therapy:[1]

• Third line and later: median overall survival (OS) was 10.0 versus 5.0 months. This was a primary endpoint, reported as statistically significant.
• Second line and later overall: median progression-free survival (PFS) was 4.2 versus 3.8 months, assessed by blinded independent central review. This was the other primary endpoint and did not reach statistical significance.
• Second line and later overall: median OS was 10.6 versus 6.4 months. This was a key secondary endpoint, reported as statistically significant.

Third-line treatment follows at least two prior lines of therapy. Those patients are also part of the broader second-line-and-later population.

The two OS analyses therefore should not be counted as independent replications in separate trials. Nor should the overall population’s 10.6-month median be presented as the result for the primary OS endpoint.

The trial’s two primary endpoints ask different questions in different, overlapping populations. That distinction matters when deciding what each result supports.

Why scrutinize PFS when patients lived longer?

OS measures time from randomization to death from any cause. PFS measures time from randomization to disease progression or death, whichever occurs first.[2]

Longer survival is an important patient benefit. The missed PFS endpoint nevertheless leaves information that deserves examination.

The endpoints can be influenced by different factors. PFS depends on imaging schedules, progression assessments and the handling of missing evaluations. OS can also be affected by treatments received after progression. These are questions to investigate when interpreting the divergence; the announcement alone cannot establish which, if any, explains this result.[2]

AstraZeneca also reported a more favorable exploratory PFS assessment by investigators.[1] An exploratory assessment cannot simply replace the prespecified independent review.

The appropriate interpretation preserves the observed survival benefit while examining whether the differences across assessments have a robust explanation.

Does a missed primary endpoint make the trial a failure?

That depends on how success was defined in advance.

FDA guidance on multiple endpoints distinguishes between studies that must demonstrate effects on several critical aspects of a disease and studies in which one or more endpoints may provide independent support. In the latter case, the testing strategy needs to control the increased chance of false conclusions from multiple comparisons.[3]

Having two primary endpoints does not, by itself, establish that both must succeed.

For CLARITY-Gastric01, a full assessment requires checking the prespecified statistical thresholds, testing sequence and consequences of a missed endpoint for other formal conclusions. The clinical importance of a survival result and the claims it supports within the statistical framework are related but distinct questions.

Without reviewing the full protocol and statistical analysis plan, and before a regulatory assessment, a simple verdict of complete success or failure would leave too much unexplained.

The investment questions: eligible patients and economic returns

The population supported by the evidence will influence the product’s commercial opportunity.

A future indication confined to third line and later would occupy a different treatment position and serve a different patient pool from a broader second-line-and-later indication. Testing requirements, relevant comparator treatments, tolerability and subsequent treatment options also need to be assessed.

These questions extend beyond clinical development.

Sone-Ve comes from an exclusive global license with KYM Biosciences. AstraZeneca’s 2023 disclosure described a $63 million upfront payment, up to $1.1 billion in potential development and sales milestones, and tiered royalties.[4]

Estimating potential returns therefore requires accounting for further development, manufacturing, commercialization and license-related payments. Potential milestones should not be treated as an acquisition price already paid in full. Global development and commercialization rights also carry contractual obligations that can affect future cash flows.

BioStockEdge’s assessment is that the reported OS findings strengthen Sone-Ve’s clinical foundation. The next stage of valuation should focus on the indication it could secure, its position in the treatment pathway and the net cash flows that position could generate.

The useful task now is to identify which conclusions have strong support and which still require the full statistical framework, detailed data and regulatory review.

Clinical figures follow company disclosures; endpoint interpretation draws on public FDA guidance. Commercial assessments are BioStockEdge’s editorial judgments. Any accompanying site-generated BioScore is separate from this assessment.

BioStockEdge Editor’s Note · Before the Conclusion
For research and education; not an individualized investment recommendation.

---

Sources and evidence status

1. AstraZeneca, October 25, 2026: Detailed CLARITY-Gastric01 results. Source for the reported populations, endpoint roles, figures and distinction between independent review and exploratory investigator assessment. This article does not infer a complete statistical testing sequence from the announcement.
2. FDA, December 2018: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Provides context for OS, PFS and their interpretation; it is not a regulatory assessment of Sone-Ve.
3. FDA, October 2022: Multiple Endpoints in Clinical Trials. Explains multiple primary endpoints, co-primary endpoints and control of multiplicity.
4. AstraZeneca, March 30, 2023: Completion of the KYM/CMG901 global license agreement. Source for the original licensing terms. These terms are not used to infer how much has subsequently been paid in milestones.